Engineers Gate Manager’s Akero Therapeutics AKRO Stock Holding History

Engineers Gate Manager’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-7,474	Closed	-$399K	–	2129
2025 Q2	$399K	Buy	+7,474	New	+$340K	0.01%	1581
2024 Q3	–	Sell	-9,270	Closed	-$217K	–	2085
2024 Q2	$217K	Sell	9,270 -8,489	-48%	-$182K	﹤0.01%	1618
2024 Q1	$449K	Buy	+17,759	New	+$427K	0.01%	1246
2023 Q4	–	Sell	-14,280	Closed	-$722K	–	1944
2023 Q3	$722K	Buy	14,280 +6,954	+95%	+$324K	0.03%	894
2023 Q2	$342K	Sell	7,326 -1,392	-16%	-$63.8K	0.01%	1246
2023 Q1	$334K	Buy	+8,718	New	+$389K	0.01%	1189
2022 Q3	–	Sell	-28,899	Closed	-$273K	–	1576
2022 Q2	$273K	Buy	+28,899	New	+$301K	0.01%	1474

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Engineers Gate Manager's AKRO Position: Q3 2025 in Review

Engineers Gate Manager sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 7,474 shares — an estimated $399K sold.

Engineers Gate Manager first reported a position in AKRO in Q2 2022 and held it in 7 quarters. The position peaked at $722K in Q3 2023. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

Engineers Gate Manager reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
Engineers Gate Manager sold 7,474 Akero Therapeutics shares in Q3 2025, an estimated $399K.
Engineers Gate Manager first reported a position in Akero Therapeutics in Q2 2022 and held it in 7 quarters.
Engineers Gate Manager's Akero Therapeutics position peaked at $722K in Q3 2023.
265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Engineers Gate Manager's 13F filing for Q3 2025, filed 14 Nov 2025.